WO1999059571A1 - Utilisation d'inhibiteurs d'amyloides pour une modulation de mort de cellules neuronales - Google Patents

Utilisation d'inhibiteurs d'amyloides pour une modulation de mort de cellules neuronales Download PDF

Info

Publication number
WO1999059571A1
WO1999059571A1 PCT/IB1999/000968 IB9900968W WO9959571A1 WO 1999059571 A1 WO1999059571 A1 WO 1999059571A1 IB 9900968 W IB9900968 W IB 9900968W WO 9959571 A1 WO9959571 A1 WO 9959571A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
interferer
receptor
group
amino
Prior art date
Application number
PCT/IB1999/000968
Other languages
English (en)
Inventor
Francine Gervais
Louis R. Lamontagne
Original Assignee
Neurochem, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem, Inc. filed Critical Neurochem, Inc.
Priority to CA002333203A priority Critical patent/CA2333203A1/fr
Priority to EP99919499A priority patent/EP1077690A1/fr
Priority to AU37262/99A priority patent/AU3726299A/en
Priority to IL13968899A priority patent/IL139688A0/xx
Priority to JP2000549236A priority patent/JP2002515429A/ja
Priority to MXPA00011213A priority patent/MXPA00011213A/es
Publication of WO1999059571A1 publication Critical patent/WO1999059571A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to methods for modulating neuronal cell death.
  • Amyloid- ⁇ is a neurotoxic peptide which is implicated in the pathogenesis of Alzheimer's Disease.
  • extracellular deposition of A ⁇ peptide in specific regions of the brain is one of the hallmarks of Alzheimer's Disease.
  • a ⁇ peptide is derived from a normal proteolytic cleavage of the precursor protein, the Amyloid- ⁇ precursor protein ( ⁇ APP). Once deposited into the brain, the A ⁇ peptide forms senile plaques which have been found in greater numbers in the brains of patients with Alzheimer's Disease. The A ⁇ peptide has also been shown to infiltrate cerebrovascular walls and cause angiopathy.
  • a progressive neuronal cell loss accompanies the deposition of A ⁇ amyloid fibrils in senile plaques.
  • the A ⁇ peptide has been shown by several groups to be highly toxic to neurons.
  • the amyloid plaques are directly associated with reactive gliosis, dystrophic neurites and apoptotic cells, suggesting that plaques induce neurodegenerative changes.
  • a ⁇ has been shown to be necrotic in rat PC- 12 cells while it induces apoptosis in primary hippocampal culture from fetal rat and in the predifferentiated human neurotype SH-SY5Y cell line (Li et al. (1996) Brain Research 738:196-204).
  • a ⁇ fibrils can induce neurodegeneration. It has been hypothesized that such an activity was due to the acquisition of the ⁇ -sheet structure of A ⁇ . Non-fibrillar A ⁇ has also been shown to be cytotoxic to neurons. La Ferla et al. ((1997) J. Clin. Invest. 100(2):310-320) have recently shown that when neuronal cells are exposed in vitro to soluble A ⁇ they can become apoptotic. Once internalized, the A ⁇ peptide gets stabilized and induces DNA fragmentation, which is characteristic of apoptosis.
  • GAGs Basement membrane glycosaminoglycans
  • Nerve growth factor has also been shown to potentiate the neurotoxicity of A ⁇ on differentiated hippocampal neurons in culture (Yankner B.A. et al. (1990) Proc. Natl. Acad. Sci. 87:9020-23). It has been suggested that ⁇ -amyloid deposits may cause induction of NGF receptor in neuronal cell types, typically unresponsive to NGF. The mechanisms and specific molecules involved in neuronal cell death, e.g., A ⁇ peptide-induced neuronal cell death, still remain uncertain. As a result, to date, effective treatments for states associated with neuronal cell death, e.g., neurodegenerative disorders, have not been developed. Accordingly, methods for inhibiting neuronal cell death are still needed.
  • the present invention provides methods for inhibiting neuronal cell death, e.g., A ⁇ -induced neuronal cell death and/or p75 receptor-mediated neuronal cell death.
  • the present invention is based, at least in part, on the discovery that compounds which interfere with the association of the A ⁇ peptide, e.g., the association of the A ⁇ peptide to the sulfate GAGs present at the cell surface, and prevent the triggering of neuronal cell apoptosis or necrosis.
  • this invention pertains to a method of inhibiting A ⁇ -induced neuronal cell death.
  • the method includes contacting a neuronal cell with an A ⁇ - interferer, such that neuronal cell death is inhibited.
  • the A ⁇ -interferer can interfere with the ability of the A ⁇ peptide to form amyloid fibrilsand/or with the ability of the A ⁇ peptide to bind to a cell surface molecule.
  • the cell surface molecule can be, for example, a neurotrophic receptor, e.g., the apoptosis-related p75 receptor; a protein presented by plasma protein, e.g., RAGE; or a glycosaminoglycan.
  • the A ⁇ peptide can be either in soluble form or in a fibril form.
  • the A ⁇ -interferer is selected from the group consisting of ethanesulfonic acid, 1 ,2-ethanedisulfonic acid, 1 -propanesulfonic acid, 1,3- propanedisulfonic acid, 1 ,4-butanedisulfonic acid, 1,5-pentanedisulfonic acid, 2- aminoethanesulfonic acid, 4-hydroxybutane-l -sulfonic acid, and pharmaceutically acceptable salts thereof.
  • the A ⁇ -interferer is selected from the group consisting of 1 -butanesulfonic acid, 1-decanesulfonic acid, 2- propanesulfonic acid, 3-pentanesulfonic acid, 4-heptanesulfonic acid, and pharmaceutically acceptable salts thereof.
  • the A ⁇ -interferer is 1 ,7-dihydroxy-4-heptanesulfonic acid, 3-amino-l-propanesulfonic acid, or a pharmaceutically acceptable salt thereof.
  • the A ⁇ is a peptide or a peptidomimetic which interact with specific regions of the AB peptide such as the regions responsible for cellular adherence (aa 10-16), GAG binding site region (13-16) or the region responsible for the ⁇ -sheet formation (16-21). These peptides are the d-stereoisomers of the A ⁇ or complementary image of the A ⁇ peptide.
  • Another aspect of the invention pertains to a method of providing neuroprotection to a subject, comprising administering an A ⁇ -interferer to the subject, such that neuroprotection is provided.
  • the A ⁇ -interferer interferes with the ability of the A ⁇ peptide to bind to a cell surface molecule, e.g., a neurotrophic receptor such as the apoptosis-related p75 receptor; a protein presented by plasma protein, e.g., RAGE; or a glycosaminoglycan.
  • a cell surface molecule e.g., a neurotrophic receptor such as the apoptosis-related p75 receptor
  • a protein presented by plasma protein e.g., RAGE
  • glycosaminoglycan e.g., a glycosaminoglycan.
  • the A ⁇ peptide can be either in soluble form or in a fibril form.
  • the A ⁇ -interferer is selected from the group consisting of ethanesulfonic acid, 1,2-ethanedisulfonic acid, 1 -propanesulfonic acid, 1,3- propanedisulfonic acid, 1 ,4-butanedisulfonic acid, 1,5-pentanedisulfonic acid, 2- aminoethanesulfonic acid, 4-hydroxybutane-l -sulfonic acid, and pharmaceutically acceptable salts thereof.
  • the A ⁇ -interferer is selected from the group consisting of 1 -butanesulfonic acid, 1-decanesulfonic acid, 2- propanesulfonic acid, 3-pentanesulfonic acid, 4-heptanesulfonic acid, and pharmaceutically acceptable salts thereof.
  • the A ⁇ -interferer is 1 ,7-dihydroxy-4-heptanesulfonic acid, 3-amino-l-propanesulfonic acid, or a pharmaceutically acceptable salt thereof.
  • the A ⁇ -interferer is administered in a pharmaceutically acceptable formulation.
  • the pharmaceutically acceptable formulation can be a dispersion system, for example a lipid-based formulation, a liposome formulation, or a multivesicular liposome formulation.
  • the pharmaceutically acceptable formulation can also comprise a polymeric matrix, selected, for example, from synthetic polymers such as polyesters (PLA, PLGA), polyethylene glycol, poloxomers, polyanhydrides, and pluronics or selected from naturally derived polymers, such as albumin, alginate, cellulose derivatives, collagen, fibrin, gelatin, and polysaccharides.
  • the pharmaceutically acceptable formulation provides sustained delivery of the A ⁇ -interferer to a subject.
  • Yet another aspect of the invention pertains to a method of treating a disease state characterized by A ⁇ -induced neuronal cell death in a subject.
  • the method includes administering an A ⁇ -interferer to the subject, such that the disease state characterized by A ⁇ -induced neuronal cell death is treated.
  • Another aspect of the invention pertains to a method of inhibiting p75 receptor mediated neuronal cell death.
  • the method includes contacting a neuronal cell with a therapeutic compound having the structure: Q— [— Y-X+] n wherein Y" is an anionic group at physiological pH; Q is a carrier group; X + is a cationic group; and n is an integer selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound, provided that the therapeutic compound is not chondroitin sulfate A, such that neuronal cell death is inhibited.
  • a further aspect of the invention pertains to a method of providing neuroprotection to a subject.
  • the method includes administering to the subject a therapeutic compound having the structure:
  • Y is an anionic group at physiological pH
  • Q is a carrier group
  • X + is a cationic group
  • n is an integer selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound, provided that the therapeutic compound is not chondroitin sulfate A, such that neuroprotection is provided.
  • the invention features a method of treating a disease state in a subject characterized by p75 receptor mediated neuronal cell death.
  • the method includes administering to the subject a therapeutic compound having the structure:
  • Y is an anionic group at physiological pH
  • Q is a carrier group
  • X + is a cationic group
  • n is an integer selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound, provided that the therapeutic compound is not chondroitin sulfate A, such that the disease state characterized by p75 receptor mediated neuronal cell death is treated.
  • the invention features a method of inhibiting p75 receptor- mediated neuronal cell death.
  • the method includes contacting a neuronal cell with a p75 receptor-interferer having the structure:
  • Z is XR 2 or R 4 ;
  • R 1 and R 2 are each independently hydrogen, a substituted or unsubstituted aliphatic group, an aryl group, a heterocyclic group, or a salt-forming cation;
  • R 3 is hydrogen, lower alkyl, aryl, or a salt-forming cation;
  • R 4 is hydrogen, lower alkyl, aryl or amino;
  • X is, independently for each occurrence, O or S;
  • Y 1 and Y 2 are each independently hydrogen, halogen, alkyl, amino, hydroxy, alkoxy, or aryloxy; and
  • n is an integer from 0 to 12, such that neuronal cell death is inhibited.
  • the invention features a method of providing neuroprotection to a subject.
  • the method includes administering to the subject a p75 receptor-interferer having the structure: in which Z is XR 2 or R 4 ; R 1 and R 2 are each independently hydrogen, a substituted or unsubstituted aliphatic group, an aryl group, a heterocyclic group, or a salt-forming cation; R 3 is hydrogen, lower alkyl, aryl, or a salt-forming cation; R 4 is hydrogen, lower alkyl, aryl or amino; X is, independently for each occurrence, O or S; Y 1 and Y 2 are each independently hydrogen, halogen, alkyl, amino, hydroxy, alkoxy, or aryloxy; and n is an integer from 0 to 12, such that neuroprotection is provided.
  • the invention features a method of treating a disease state in a subject characterized by p75 receptor-mediated neuronal cell death.
  • the method includes administering to the subject a p75 receptor-interferer having the structure:
  • R 1 and R 2 are each independently hydrogen, a substituted or unsubstituted aliphatic group, an aryl group, a heterocyclic group, or a salt-forming cation
  • R 3 is hydrogen, lower alkyl, aryl, or a salt-forming cation
  • R 4 is hydrogen, lower alkyl, aryl or amino
  • X is, independently for each occurrence, O or S
  • Y 1 and Y 2 are each independently hydrogen, halogen, alkyl, amino, hydroxy, alkoxy, or aryloxy
  • n is an integer from 0 to 12, such that said disease state characterized by p75 receptor mediated neuronal cell death is treated.
  • Figure 1 is a depiction of a bar graph showing the toxicity of A ⁇ (l-40) administered at a ratio of 1 : 1 with various A ⁇ -interferers, on PC- 12 cells.
  • Figure 2 is a depiction of a bar graph showing the toxicity of A ⁇ (l-40) administered at a ratio of 1 :2 with various A ⁇ -interferers, on PC- 12 cells.
  • Figure 3 is a depiction of a bar graph showing the % cell survival of differentiated PC- 12 cells treated with A ⁇ (l -40) and various A ⁇ -interferers at a 1 :2 and 1 :1 ratio.
  • Figure 4 is a depiction of a bar graph showing the results from an A ⁇ (l-40) mediated neurotoxicity assay on differentiated PC- 12 cells.
  • Figure 5 is a graph illustrating the ability of A ⁇ to induce neuronal cell death using the SH-5454 neuroblastoma human cell line. Toxicity was measured using 2 different assays : WST-1 assay and 3H-thiperidine uptake.
  • Figure 6 illustrates the ability of a compound of the present invention, NC-2125 to significantly reduce the A ⁇ -induced toxicity when incubated at an A ⁇ : nc-2125 molar ratio of 1 : 4, laminin, used at an A ⁇ : laminin molar ratio of 1 : 10 "3 is an internal positive control (neuroprotective).
  • the present invention is based, at least in part, on the discovery that compounds which interfere with the A ⁇ peptide, e.g., the association of the A ⁇ peptide, to sites present at the cell surface or to sulfate GAGs, and prevent the triggering of neuronal cell apoptosis or necrosis.
  • This invention pertains to a method of inhibiting A ⁇ -induced neuronal cell death.
  • the method includes contacting a neuronal cell with an A ⁇ -interferer, such that neuronal cell death is inhibited.
  • the language "contacting” is intended to include both in vivo or in vitro methods of bringing an A ⁇ -interferer or a p75 receptor-interferer into proximity with a neuronal cell, such that the A ⁇ -interferer or a p75 receptor-interferer can modulate, e.g., inhibit, the death, e.g., apoptosis, of the neuronal cell.
  • the neuronal cell can be contacted with an A ⁇ -interferer in vivo by administering the A ⁇ - interferer to a subject either parenterally, e.g., intravenously, intradermally, subcutaneously, orally (e.g., via inhalation), transdermally (topically), transmucosally, or rectally.
  • a neuronal cell can also be conducted in vitro by, for example, adding an A ⁇ - interferer or a p75 receptor-interferer into a tissue culture dish in which neuronal cells are grown.
  • the invention further pertains to a method of providing neuroprotection to a subject, comprising administering an A ⁇ -interferer to the subject, such that neuroprotection is provided.
  • the term "subject" is intended to include animals susceptible to states characterized by neuronal cell death, preferably mammals, most preferably humans.
  • the subject is a primate.
  • the primate is a human.
  • Other examples of subjects include experimental animals such as mice, rats, dogs, cats, goats, sheep, pigs, and cows.
  • the experimental animal can be an animal model for a disorder, e.g., a transgenic mouse with an Alzheimer' s-type neuropathology.
  • a subject can be a human suffering from a neurodegenerative disease, such as Alzheimer's disease, or Parkinson's disease.
  • neuroprotection is intended to include protection of neuronal cells of a subject from cell death, e.g., cell death induced by an A ⁇ peptide and/or mediated by an apoptosis related p75 receptor.
  • Neuroprotection includes, for example, inhibition of processes such as the destabilization of the cytoskeleton; the activation of hydro lytic enzymes, such as phospholipase A2, calcium-activated proteases, and calcium-activated endonucleases; the disruption of cell junctions leading to decreased or absent cell-cell communication; and the activation of expression of genes involved in cell death, e.g., immediate-early genes.
  • the method of the invention includes contacting a neuronal cell in vitro or administering to a subject in vivo, an effective amount of an A ⁇ -interferer or a p75 receptor-interferer, which has at least one anionic group covalently attached to a carrier molecule.
  • an "A ⁇ -interferer” refers to a compound which can interfere with the ability of an A ⁇ -peptide to either form A ⁇ -f ⁇ brils or interact with a cell surface molecule such as a proteoglycan constituent of a basement membrane, e.g.
  • a glycosaminoglycan a cell surface receptor, e.g., a neurotrophic receptor such as the apoptosis related p75 receptor; or a protein presented by plasma protein, e.g., RAGE.
  • An A ⁇ -interferer can interfere with the ability of both fibrillar or non-fibrillar A ⁇ to interact with a cell surface molecule, e.g., the apoptosis related p75 receptor or RAGE.
  • a "p75 receptor-interferer" refers to a compound which can interfere with the ability of the apoptosis related p75 receptor to mediate cell death in a neuronal cell.
  • the p75 receptor-interferer can block a ligand binding site on the p75 receptor, it can compete with the natural ligand for binding to the p75 receptor, or it can block the p75 receptor binding site on the natural ligand, thus preventing the ligand-receptor interaction. It should be understood that the description set forth below regarding particular compounds, and formulae is applicable to both examples of A ⁇ -interferers and P75 receptor-interferers.
  • the A ⁇ -interferer or p75 receptor-interferer can have the structure:
  • Y" is an anionic group at physiological pH
  • Q is a carrier group
  • X + is a cationic group
  • n is an integer.
  • the number of anionic groups (“n") is selected such that the biodistribution of the A ⁇ -interferer or p75 receptor-interferer for an intended target site is not prevented while maintaining activity of the A ⁇ -interferer or p75 receptor- interferer.
  • the number of anionic groups is not so great as to prevent traversal of an anatomical barrier, such as a cell membrane, or entry across a physiological barrier, such as the blood-brain barrier, in situations where such properties are desired.
  • n is an integer between 1 and 10. In another embodiment, n is an integer between 3 and 8.
  • An anionic group of an A ⁇ -interferer of the invention is a negatively charged moiety that, when attached to a carrier group, can inhibit an A ⁇ -peptide from either forming A ⁇ -fibrils or interacting with a cell surface molecule such as a proteoglycan constituent of a basement membrane, e.g. a glycosaminoglycan, a cell surface receptor, e.g., a neurotrophic receptor such as the apoptosis related p75 receptor, or a protein presented by plasma protein, e.g., RAGE, thus preventing neuronal cell death.
  • a cell surface molecule such as a proteoglycan constituent of a basement membrane, e.g. a glycosaminoglycan, a cell surface receptor, e.g., a neurotrophic receptor such as the apoptosis related p75 receptor, or a protein presented by plasma protein, e.g., RAGE, thus preventing neuronal cell death.
  • An anionic group of a p75 receptor-interferer of the invention is a negatively charged moiety that, when attached to a carrier group, can inhibit the apoptosis related p75 receptor from mediating cell death in a neuronal cell.
  • the anionic group is negatively charged at physiological pH.
  • the anionic A ⁇ -interferer mimics the structure of a sulfated proteoglycan, i.e., is a sulfated compound or a functional equivalent thereof.
  • “Functional equivalents" of sulfates are intended to include compounds such as sulfamates as well as bioisosteres.
  • Bioisosteres encompass both classical bioisosteric equivalents and non-classical bioisosteric equivalents.
  • Classical and non-classical bioisosteres of sulfate groups are known in the art (see e.g. Silverman, R.B. The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc.: San Diego, CA, 1992, pp.19-23).
  • an A ⁇ -interferer of the invention can comprise at least one anionic group including sulfonates, sulfates, sulfamates, phosphonates, phosphates, carboxylates, and heterocyclic groups of the following formulas:
  • the multiple anionic groups can be the same structural group (e.g., all sulfonates) or, alternatively, a combination of different anionic groups can be used (e.g., sulfonates, phosphonates, and sulfates, etc.).
  • an A ⁇ -interferer of the invention to inhibit an interaction between an A ⁇ peptide and a glycoprotein or proteoglycan constituent of a basement membrane can be assessed by an in vitro binding assay, such as the one described in Leveugle B. et al. (1998) J. of Neurochem. 70(2):736-744. Briefly, a constituent of the basement membrane, preferably a glycosaminoglycan (GAG) can be radiolabeled, e.g., at a specific activity of 10,000 cpm, and then incubated with A ⁇ peptide-Sepharose beads at, for example, a ratio of 5:1 (v/v) in the presence or absence of the A ⁇ -interferer.
  • GAG glycosaminoglycan
  • the A ⁇ peptide-Sepharose beads and the radiolabeled GAG can be incubated for approximately 30 minutes at room temperature and then the beads can be successively washed with a Tris buffer solution containing NaCl (0.55 M and 2 M).
  • the binding of the basement membrane constituent (e.g., GAG) to the A ⁇ -peptide can then be measured by collecting the fractions from the washings and subjecting them to scintillation counting.
  • An A ⁇ -interferer which inhibits an interaction between an A ⁇ peptide and a glycoprotein or proteoglycan constituent of a basement membrane, e.g., GAG, will increase the amount of radioactivity detected in the washings.
  • an A ⁇ -interferer of the invention interacts with a binding site for a basement membrane glycoprotein or proteoglycan in an A ⁇ peptide and thereby inhibits the binding of the A ⁇ peptide to the basement membrane constituent, e.g., GAG.
  • Basement membrane glycoproteins and proteoglycans include GAG, laminin, collagen type IV, fibronectin, and heparan sulfate proteoglycan (HSPG).
  • the therapeutic compound inhibits an interaction between an A ⁇ peptide and GAG. Consensus binding site motifs for GAG in amyloidogenic proteins have been described (see, for example, Hileman R. E. et al. (1998) BioEssays 20: 156-167).
  • a GAG consensus binding motif can be of the general formula X-B-B-X-B-X or X-B-B-B-X-X-B-X, wherein B are basic amino acids (e.g., lysine or arginine) and X are hydropathic amino acids.
  • a GAG consensus binding motif can further be of the general formula T-X-X-B-X-X-T-B-X-X-X-T-B-B-X-X-X-T-B-B, wherein T defines a turn of a basic amino acid, Bs are basic amino acids (e.g., lysine, arginine, or occasionally glutamine) and X are hydropathic amino acids.
  • the distance between the first and the second turn can range from approximately 12 A to 17A.
  • the distance between the second and the third turn can be approximately 14 A.
  • the distance between the first and the third turn can range from approximately 13 A to 18 A.
  • the GAG binding site domain of A ⁇ i.e. the 13-16 resion: HHQK
  • HHQK 13-16 resion domain of A ⁇
  • the relative spacing of the anionic groups can be chosen such that the anionic groups (e.g., sulfonates or phosphonates) optimally interact with the basic residues within the GAG binding site (thereby inhibiting interaction of GAG with the site).
  • anionic groups can be spaced approximately 15 ⁇ 1.5 A, 14 ⁇ 1.5 A and/or 16 ⁇ 1.5 A apart, or appropriate multiples thereof, such that the relative spacing of the anionic groups allows for optimal interaction with a binding site for a basement membrane constituent (e.g., GAG) in an A ⁇ peptide.
  • a p75 receptor-interferer of the invention can block a ligand binding site on the p75 receptor, it can compete with the natural ligand for binding to the p75 receptor, or it can block the p75 receptor binding site on the natural ligand.
  • An A ⁇ -interferer or p75 receptor-interferer of the invention typically further comprises a counter cation (i.e., X + in the general formula: Q — [ — Y ⁇ X + ] n ).
  • Cationic groups include positively charged atoms and moieties. If the cationic group is hydrogen, H + , then the compound is considered an acid, e.g., ethanesulfonic acid.
  • the compound is a salt of the acid.
  • Pharmaceutically acceptable salts of the A ⁇ -interferer or p75 receptor-interferer are within the scope of the invention.
  • X + can be a pharmaceutically acceptable alkali metal, alkaline earth, higher valency cation, polycationic counter ion or ammonium.
  • a preferred pharmaceutically acceptable salt is a sodium salt but other salts are also contemplated within their pharmaceutically acceptable range.
  • the anionic group(s) is covalently attached to a carrier group.
  • Suitable carrier groups include aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups, and groups derived from carbohydrates, polymers, peptides, peptide derivatives, or combinations thereof.
  • a carrier group can be substituted, e.g. with one or more amino, nitro, halogen, thiol or hydroxyl groups.
  • Carbohydrate is intended to include substituted and unsubstituted mono-, oligo-, and polysaccharides.
  • Monosaccharides are simple sugars usually of the formula C6H12O6 that can be combined to form oligosaccharides or polysaccharides.
  • Monosaccharides include enantiomers and both the D and L stereoisomers of monosaccharides.
  • Carbohydrates can have multiple anionic groups attached to each monosaccharide moiety. For example, in sucrose octasulfate, four sulfate groups are attached to each of the two monosaccharide moieties.
  • polymer is intended to include molecules formed by the chemical union of two or more combining subunits called monomers.
  • Monomers are molecules or compounds which usually contain carbon and are of relatively low molecular weight and simple structure. A monomer can be converted to a polymer by combination with itself or other similar molecules or compounds.
  • a polymer may be composed of a single identical repeating subunit or multiple different repeating subunits (copolymers).
  • Polymers within the scope of this invention include substituted and unsubstituted vinyl, acryl, styrene and carbohydrate-derived polymers and copolymers and salts thereof. In one embodiment, the polymer has a molecular weight of approximately 800-1000 Daltons.
  • polymers with suitable covalently attached anionic groups include poly(2-acrylamido-2- methyl- 1 -propanesulfonic acid); poly(2-acrylamido-2-methyl- 1 -propanesulfonic acid-co- acrylonitrile); poly(2-acrylamido-2 -methyl- 1 -propanesulfonic acid-co-styrene); poly(vinylsulfonic acid); poly(sodium 4-styrenesulfonic acid); and sulfates and/or sulfonates derived from: poly(acrylic acid); poly(methyl acrylate); poly(methyl methacrylate); and poly(vinyl alcohol); and pharmaceutically acceptable salts thereof.
  • polymers with suitable covalently attached anionic groups include those of the formula:
  • R is SO3H or OSO3H; and pharmaceutically acceptable salts thereof.
  • Peptides and peptide derivatives can also act as carriers.
  • the term "peptide" includes two or more amino acids covalently attached through a peptide bond.
  • Amino acids which can be used in peptide carrier include those naturally occurring amino acids found in proteins such as glycine, alanine, valine, cysteine, leucine, isoleucine, serine, threonine, methionine, glutamic acid, aspartic acid, glutamine, asparagine, lysine, arginine, proline, histidine, phenylalanine, tyrosine, and tryptophan.
  • amino acid further includes analogs, derivatives and congeners of naturally occurring amino acids, one or more of which can be present in a peptide derivative.
  • amino acid analogs can have lengthened or shortened side chains or variant side chains with appropriate functional groups.
  • D and L stereoisomers of an amino acid when the structure of the amino acid admits of stereoisomeric forms.
  • peptide derivative further includes compounds which contain molecules which mimic a peptide backbone but are not amino acids (so-called peptidomimetics), such as benzodiazepine molecules (see e.g. James, G. L. et al. (1993) Science 260:1937-1942).
  • the anionic groups can be attached to a peptide or peptide derivative through a functional group on the side chain of certain amino acids or other suitable functional group.
  • a sulfate group can be attached through the hydroxyl side chain of a serine residue.
  • a peptide can be designed to interact with a binding site for a basement membrane constituent (e.g., a GAG) in an A ⁇ -peptide (as described above).
  • the peptide comprises four amino acids and anionic groups (e.g., sulfonates) are attached to the first, second and fourth amino acid.
  • the peptide can be Ser-Ser-Y-Ser, wherein an anionic group is attached to the side chain of each serine residue and Y is any amino acid.
  • single amino acids can be used as carriers in the A ⁇ -interferer or p75 receptor-interferer of the invention.
  • cysteic acid the sulfonate derivative of cysteine, can be used.
  • aliphatic group is intended to include organic compounds characterized by straight or branched chains, typically having between 1 and 22 carbon atoms. Aliphatic groups include alkyl groups, alkenyl groups and alkynyl groups. In complex structures, the chains can be branched or cross-linked. Alkyl groups include saturated hydrocarbons having one or more carbon atoms, including straight-chain alkyl groups and branched-chain alkyl groups. Such hydrocarbon moieties may be substituted on one or more carbons with, for example, a halogen, a hydroxyl, a thiol, an amino, an alkoxy, an alkylcarboxy, an alkylthio, or a nitro group.
  • lower aliphatic as used herein means an aliphatic group, as defined above (e.g., lower alkyl, lower alkenyl, lower alkynyl), but having from one to six carbon atoms.
  • Representatives of such lower aliphatic groups, e.g., lower alkyl groups are methyl, ethyl, n-propyl, isopropyl, 2-chloropropyl, n-butyl, sec-butyl, 2- aminobutyl, isobutyl, tert-butyl, 3-thiopentyl, and the like.
  • amino means -NH2; the term “nitro” means -NO2; the term “halogen” designates -F, - Cl, -Br or -I; the term “thiol” means SH; and the term “hydroxyl” means -OH.
  • alkylamino as used herein means -NHR in which R is an alkyl group as defined above.
  • alkylthio refers to -SR, in which R is an alkyl group as defined above.
  • alkylcarboxyl as used herein means -COOR, in which R is an alkyl group as defined above.
  • alkoxy as used herein means -OR, in which R is an alkyl group as defined above.
  • Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.
  • alkenyl and alkynyl refer to unsaturated aliphatic groups analogous to alkyls, but which contain at least one double or triple bond respectively.
  • alicyclic group is intended to include closed ring structures of three or more carbon atoms.
  • Alicyclic groups include cycloparaffms or naphthenes which are saturated cyclic hydrocarbons, cycloolefins which are unsaturated with two or more double bonds, and cycloacetylenes which have a triple bond. They do not include aromatic groups.
  • Examples of cycloparaffms include cyclopropane, cyclohexane, and cyclopentane.
  • cycloolefins include cyclopentadiene and cyclooctatetraene.
  • Alicyclic groups also include fused ring structures and substituted alicyclic groups such as alkyl substituted alicyclic groups.
  • such substituents can further comprise a lower alkyl, a lower alkenyl, a lower alkoxy, a lower alkylthio, a lower alkylamino, a lower alkylcarboxyl, a nitro, a hydroxyl, -CF3, -CN, or the like.
  • the term "heterocyclic group” is intended to include closed ring structures in which one or more of the atoms in the ring is an element other than carbon, for example, nitrogen, or oxygen. Heterocyclic groups can be saturated or unsaturated and heterocyclic groups such as pyrrole and furan can have aromatic character. They include fused ring structures such as quinoline and isoquinoline.
  • heterocyclic groups include pyridine and purine.
  • Heterocyclic groups can also be substituted at one or more constituent atoms with, for example, a halogen, a lower alkyl, a lower alkenyl, a lower alkoxy, a lower alkylthio, a lower alkylamino, a lower alkylcarboxyl, a nitro, a hydroxyl, -CF3, -CN, or the like.
  • aromatic group is intended to include unsaturated cyclic hydrocarbons containing one or more rings.
  • Aromatic groups include 5- and 6- membered single-ring groups which may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
  • the aromatic ring may be substituted at one or more ring positions with, for example, a halogen, a lower alkyl, a lower alkenyl, a lower alkoxy, a lower alkylthio, a lower alkylamino, a lower alkylcarboxyl, a nitro, a hydroxyl, -CF3, -CN, or the like.
  • the A ⁇ -interferer administered to the subject is comprised of at least one sulfonate group covalently attached to a carrier group, or a pharmaceutically acceptable salt thereof.
  • the an A ⁇ -interferer or a p75 receptor-interferer can have the structure:
  • n is an integer. Suitable carrier groups and cationic groups are those described hereinbefore.
  • the number of sulfonate groups ("n") is selected such that the biodistribution of the compound for an intended target site is not prevented while maintaining activity of the compound as discussed earlier.
  • n is an integer between 1 and 10.
  • n is an integer between 3 and 8.
  • an A ⁇ -interferer or a p75 receptor- interferer with multiple sulfonate groups can have the sulfonate groups spaced such that the compound interacts optimally with an HSPG binding site within the A ⁇ peptide.
  • the carrier group for a sulfonate(s) is a lower aliphatic group (e.g., a lower alkyl, lower alkenyl or lower alkynyl), a heterocyclic group, and group derived from a disaccharide, a polymer or a peptide or peptide derivative.
  • the carrier can be substituted, e.g. with one or more amino, nitro, halogeno, sulfhydryl or hydroxyl groups.
  • the carrier for a sulfonate(s) is an aromatic group.
  • Suitable sulfonated polymeric A ⁇ -interferers include poly(2- acrylamido-2 -methyl- 1 -propanesulfonic acid); poly(2-acrylamido-2-methyl- 1 - propanesulfonic acid-co-acrylonitrile); poly (2-acrylamido-2 -methy 1-1 -propanesulfonic acid-co-styrene); poly(vinylsulfonic acid); poly(sodium 4-styrenesulfonic acid); a sulfonic acid derivative of poly(acrylic acid); a sulfonic acid derivative of poly(methyl acrylate); a sulfonic acid derivative of poly(methyl methacrylate); and a sulfonate derivative of poly(vinyl alcohol); and pharmaceutically acceptable salts thereof.
  • a preferred sulfonated polymer is poly(vinylsulfonic acid) (PVS) or a pharmaceutically acceptable salt thereof, preferably the sodium salt thereof.
  • PVS having a molecular weight of about 800-1000 Daltons is used. PVS may be used as a mixture of stereoisomers or as a single active isomer.
  • Preferred sulfonated saccharides include 5-deoxy-l,2-O-isopropylidene- ⁇ -D- xylofuranose-5-sulfonic acid (XXIII, shown as the sodium salt).
  • Preferred lower aliphatic sulfonated A ⁇ -interferers for use in the invention include ethanesulfonic acid; 2-aminoethanesulfonic acid (taurine); cysteic acid (3- sulfoalanine or ⁇ -amino- ⁇ -sulfopropionic acid); 1 -propanesulfonic acid; 1,2- ethanedisulfonic acid; 1,3-propanedisulfonic acid; 1 ,4-butanedisulfonic acid; 1,5- pentanedisulfonic acid; and 4-hydroxybutane-l -sulfonic acid (VIII, shown as the sodium salt); and pharmaceutically acceptable salts thereof.
  • VIII shown as the sodium salt
  • aliphatic sulfonated A ⁇ - interferers contemplated for use in the invention include 1 -butanesulfonic acid (XL VII, shown as the sodium salt), 2-propanesulfonic acid (XLIX, shown as the sodium salt), 3- pentanesulfonic acid (L, shown as the sodium salt), 4-heptanesulfonic acid (LII, shown as the sodium salt), 1-decanesulfonic acid (XLVIII, shown as the sodium salt); and pharmaceutically acceptable salts thereof.
  • Sulfonated substituted aliphatic A ⁇ - interferers contemplated for use in the invention include 3-amino-l-propanesulfonic acid (XXII, shown as the sodium salt), 3-hydroxy-l -propanesulfonic acid sulfate (XXXV, shown as the disodium salt), 1 ,7-dihydroxy-4-heptanesulfonic acid (LIII, shown as the sodium salt); and pharmaceutically acceptable salts thereof.
  • Yet other sulfonated compounds contemplated for use in the invention include 2-[(4- pyridinyl)amido] ethanesulfonic acid (LIV, depicted as the sodium salt), and pharmaceutically acceptable salts thereof.
  • Preferred heterocyclic sulfonated A ⁇ -interferers include 3-(N-morpholino)-l- propanesulfonic acid; and tetrahydrothiophene-1 ,1 -dioxide-3,4-disulfonic acid; and pharmaceutically acceptable salts thereof.
  • Aromatic sulfonated A ⁇ -interferers include 1,3-benzenedisulfonic acid (XXXVI, shown as the disodium salt), 2,5-dimethoxy-l,4-benzenedisulfonic acid (depicted as the disodium salt, XXXVII, or the dipotassium salt, XXXIX), 4-amino-3-hydroxy-l- naphthalenesulfonic acid (XLIII), 3,4-diamino-l -naphthalenesulfonic acid (XLIV); and pharmaceutically acceptable salts thereof.
  • the A ⁇ -interferer administered to the subject is comprised of at least one sulfate group covalently attached to a carrier group, or a pharmaceutically acceptable salt thereof.
  • the A ⁇ - interferer or the p75 receptor-interferer can have the structure:
  • n is an integer. Suitable carriers and cationic groups are those described hereinbefore.
  • the number of sulfate groups ("n") is selected such that the biodistribution of the compound for an intended target site is not prevented while maintaining activity of the A ⁇ -interferer as discussed earlier.
  • n is an integer between 1 and 10.
  • n is an integer between 3 and 8.
  • an A ⁇ -interferer with multiple sulfate groups can have the sulfate groups spaced such that the compound interacts optimally with a GAG binding site within an A ⁇ peptide.
  • the carrier group for a sulfate(s) is a lower aliphatic group (e.g., a lower alkyl, lower alkenyl or lower alkynyl), an aromatic group, a group derived from a disaccharide, a polymer or a peptide or peptide derivative.
  • the carrier can be substituted, e.g. with one or more amino, nitro, halogeno, sulfhydryl or hydroxyl groups.
  • Suitable sulfated polymeric A ⁇ -interferers or p75 receptor- interferers include poly(2-acrylamido-2-methyl-propyl sulfuric acid); poly(2- acrylamido-2-methyl-propyl sulfuric acid-co-acrylonitrile); poly(2-acrylamido-2-methyl- propyl sulfuric acid-co-styrene); poly(vinylsulfuric acid); poly(sodium 4-styrenesulfate); a sulfate derivative of poly(acrylic acid); a sulfate derivative of poly(methyl acrylate); a sulfate derivative of poly (methyl methacrylate); and a sulfate derivative of poly (vinyl alcohol); and pharmaceutically acceptable salts thereof.
  • a preferred sulfated polymer is poly(vinylsulfuric acid) or pharmaceutically acceptable salt thereof.
  • a preferred sulfated disaccharide is sucrose octasulfate or pharmaceutically acceptable salt thereof.
  • Other sulfated saccharides contemplated for use in the invention include the acid form of methyl- ⁇ -D-glucopyranoside 2,3-disulfate (XVI), methyl 4,6- O-benzylidene- ⁇ -D-glucopyranoside 2,3-disulfate (XVII), 2,3,4,3',4'-sucrose pentasulfate (XXXIII), 1 ,3 :4,6-di-O-benzylidene-D-mannitol 2,5-disulfate (XLI), D- mannitol 2,5-disulfate (XLII), 2,5-di-O-benzyl-D-mannitol tetrasulfate (XLV); and pharmaceutically acceptable salts thereof.
  • Preferred lower aliphatic sulfated A ⁇ -interferers for use in the invention include ethyl sulfuric acid; 2-aminoethan-l-ol sulfuric acid; 1-propanol sulfuric acid; 1,2- ethanediol disulfuric acid; 1,3-propanediol disulfuric acid; 1 ,4-butanediol disulfuric acid; 1,5-pentanediol disulfuric acid; and 1 ,4-butanediol monosulfuric acid; and pharmaceutically acceptable salts thereof.
  • sulfated aliphatic A ⁇ -interferers contemplated for use in the invention include the acid form of 1,3-cyclohexanediol disulfate (XL), 1,3,5-heptanetriol trisulfate (XIX), 2-hydroxymethyl- 1,3-propanediol trisulfate (XX), 2-hydroxymethyl-2-methyl- 1,3-propanediol trisulfate (XXI), 1,3,5,7- heptanetetraol tetrasulfate (XLVI), 1,3,5,7,9-nonane pentasulfate (LI); and pharmaceutically acceptable salts thereof.
  • XL 1,3-cyclohexanediol disulfate
  • XIX 1,3,5-heptanetriol trisulfate
  • XXX 2-hydroxymethyl- 1,3-propanediol trisulfate
  • XXI 2-hydroxymethyl-2-methyl-
  • sulfated A ⁇ -interferers contemplated for use in the invention include the acid form of 2-amino-2-hydroxymethyl- 1,3- propanediol trisulfate (XXIV), 2 -benzyloxy- 1,3-propanediol disulfate (XXIX), 3- hydroxypropylsulfamic acid sulfate (XXX)2,2'-iminoethanol disulfate (XXXI), N,N- bis(2-hydroxyethyl)sulfamic acid disulfate (XXXII); and pharmaceutically acceptable salts thereof.
  • Preferred heterocyclic sulfated A ⁇ -interferers include 3-(N-morpholino)-l -propyl sulfuric acid; and tetrahydrothiophene-3,4-diol- 1,1 -dioxide disulfuric acid; and pharmaceutically acceptable salts thereof.
  • the invention further contemplates the use of prodrugs which are converted in vivo to the A ⁇ -interferers used in the methods of the invention (see, e.g., R.B. Silverman, 1992, “The Organic Chemistry of Drug Design and Drug Action", Academic Press, Chp. 8).
  • prodrugs can be used to alter the biodistribution (e.g., to allow compounds which would not typically cross the blood-brain barrier to cross the blood- brain barrier) or the pharmacokinetics of the A ⁇ -interferer.
  • an anionic group e.g., a sulfate or sulfonate
  • the ester is cleaved, enzymatically or non-enzymatically, reductively or hydrolytically, to reveal the anionic group.
  • Such an ester can be cyclic, e.g., a cyclic sulfate or sultone, or two or more anionic moieties may be esterified through a linking group.
  • Exemplary cyclic A ⁇ -interferers include, for example, 2- sulfobenzoic acid cyclic anhydride (LV), 1,3-propane sultone (LVI), 1,4-butane sultone (LVII), 1 ,3-butanediol cyclic sulfate (LVIII), ⁇ -chloro- ⁇ -hydroxy-o-toluenesulfonic acid ⁇ -sultone (LIX), and 6-nitronaphth-[l,8-cd]-l,2,-oxathiole 2,2-dioxide (LX).
  • the prodrug is a cyclic sulfate or sultone.
  • An anionic group can be esterified with moieties (e.g.. acyloxymethyl esters) which are cleaved to reveal an intermediate A ⁇ -interferer which subsequently decomposes to yield the active A ⁇ - interferer.
  • the prodrug is a reduced form of a sulfate or sulfonate, e.g., a thiol, which is oxidized in vivo to the A ⁇ -interferer.
  • an anionic moiety can be esterified to a group which is actively transported in vivo, or which is selectively taken up by target organs. The ester can be selected to allow specific targeting of the A ⁇ -interferers to particular organs, as described below for carrier moieties.
  • Carrier groups useful in the A ⁇ -interferers include groups previously described, e.g. aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups, groups derived from carbohydrates, polymers, peptides, peptide derivatives, or combinations thereof. Suitable polymers include substituted and unsubstituted vinyl, acryl, styrene and carbohydrate-derived polymers and copolymers and salts thereof. Preferred carrier groups include a lower alkyl group, a heterocyclic group, a group derived from a disaccharide, a polymer, a peptide, or peptide derivative.
  • Carrier groups useful in the present invention may also include moieties which allow the A ⁇ -interferer to be selectively delivered to a target organ or organs.
  • the carrier group may include a moiety capable of targeting the A ⁇ -interferer to the brain, by either active or passive transport (a "targeting moiety").
  • the carrier group may include a redox moiety, as described in. for example, U.S. Patents 4.540.564 and 5.389,623, both to Bodor. These patents disclose drugs linked to dihydropyridine moieties which can enter the brain, where they are oxidized to a charged pyridinium species which is trapped in the brain.
  • Exemplary pyridine/dihdropyridine compounds of the invention include sodium 2-(nicotinylamido)-ethanesulfonate (LXII), and 1 -(3-sulfopropyl)-pyridinium betaine (LXIII).
  • Other carrier moieties include groups, such as those derived from amino acids or thyroxine. which can be passively or actively transported in vivo.
  • An illustrative compound is phenylalanyltaurine (LXIX), in which a taurine molecule is conjugated to a phenylalanine (a large neutral amino acid).
  • Such a carrier moiety can be metabolically removed in vivo, or can remain intact as part of an active A ⁇ -interferer.
  • Structural mimics of amino acids (and other actively transported moieties) are also useful in the invention (e.g., l-(aminomethyl)-l- (sulfomethyl)-cyclohexane (LXX)).
  • Other exemplary amino acid mimetics include p- (sulfomethyl)phenylalanine (LXXII), p-(l,3-disulfoprop-2-yl)phenylalanine (LXXIII), and O-(l,3-disulfoprop-2-yl)tyrosine (LXXIV).
  • Exemplary thyroxine mimetics include compounds LXXV, LXVI, and LXXVII.
  • Many targeting moieties are known, and include, for example, asialoglycoproteins (see, e.g. Wu, U.S. Patent 5,166,320) and other ligands which are transported into cells via receptor-mediated endocytosis (see below for further examples of targeting moieties which may be covalently or non-covalently bound to a carrier molecule).
  • the A ⁇ -interferers of the invention may bind to amyloidogenic proteins, e.g., A ⁇ peptide, in the circulation and thus be transported to the site of action.
  • the targeting and prodrug strategies described above can be combined to produce an A ⁇ -interferer that can be transported as a prodrug to a desired site of action and then unmasked to reveal an active A ⁇ -interferer.
  • the dihydropyrine strategy of Bodor can be combined with a cyclic prodrug, as for example in the compound 2-(l -methyl- l,4-dihydronicotinyl)amidomethyl-propanesultone (LXXI).
  • the A ⁇ -interferer in the pharmaceutical compositions is a sulfonated polymer, for example poly(2-acrylamido-2-methyl-l -propanesulfonic acid); poly(2-acrylamido-2-methyl- 1 -propanesulfonic acid-co-acrylonitrile); poly(2- acrylamido-2-methyl-l -propanesulfonic acid-co-styrene); poly(vinylsulfonic acid); poly(sodium 4-styrenesulfonic acid); a sulfonate derivative of poly(acrylic acid); a sulfonate derivative of poly(methyl acrylate); a sulfonate derivative of poly (methyl methacrylate); and a sulfonate derivative of poly(vinyl alcohol); and pharmaceutically acceptable salts thereof.
  • poly(2-acrylamido-2-methyl-l -propanesulfonic acid) poly(2-acrylamido-2-methyl- 1 -propanesul
  • the A ⁇ -interferer in the pharmaceutical compositions is a sulfated polymer, for example poly(2-acry lamido-2 -methyl- 1 -propyl sulfuric acid); poly(2-acrylamido-2 -methyl- 1 -propyl sulfuric acid-co-acrylonitrile); poly(2-acrylamido- 2-methyl-l -propyl sulfuric acid-co-styrene); poly(vinyl sulfuric acid); poly(sodium 4-styrenesulfate); a sulfate derivative of poly(acrylic acid); a sulfate derivative of poly(methyl acrylate); a sulfate derivative of poly(methyl methacrylate); and pharmaceutically acceptable salts thereof.
  • a sulfated polymer for example poly(2-acry lamido-2 -methyl- 1 -propyl sulfuric acid); poly(2-acrylamido-2 -methyl- 1 -propyl sulfuric acid-co-acrylonitrile); poly
  • the A ⁇ -interferer or p75 receptor-interferer can also have the structure:
  • Z is XR 2 or R 4 , R 1 and R 2 are each independently hydrogen, a substituted or unsubstituted aliphatic group (preferably a branched or straight-chain aliphatic moiety having from 1 to 24 carbon atoms in the chain; or an unsubstituted or substituted cyclic aliphatic moiety having from 4 to 7 carbon atoms in the aliphatic ring; preferred aliphatic and cyclic aliphatic groups are alkyl groups, more preferably lower alkyl), an aryl group, a heterocyclic group, or a salt-forming cation; R 3 is hydrogen, lower alkyl, aryl, or a salt-forming cation; X is, independently for each occurrence, O or S; R 4 is hydrogen, lower alkyl, aryl or amino; Y 1 and Y 2 are each independently hydrogen, halogen (e.g., F, Cl, Br, or I), lower alkyl, amino (including alkylamino
  • Preferred A ⁇ -interferers or p75 receptor-interferers for use in the invention include compounds in which both R 1 and R 2 are pharmaceutically acceptable salt- forming cations. It will be appreciated that the stoichiometry of an anionic compound to a salt-forming counterion (if any) will vary depending on the charge of the anionic portion of the compound (if any) and the charge of the counterion. In a particularly preferred embodiment, R 1 , R 2 and R 3 are each independently a sodium, potassium or calcium cation.
  • the aliphatic group has between 1 and 10 carbons atoms in the straight or branched chain, and is more preferably a lower alkyl group. In other embodiments in which at least one of R 1 and R 2 is an aliphatic group, the aliphatic group has between 10 and 24 carbons atoms in the straight or branched chain. In certain preferred embodiments, n is 0 or 1 ; more preferably, n is 0. In certain preferred embodiments of the therapeutic compounds, Y 1 and Y 2 are each hydrogen. In certain preferred embodiments, the A ⁇ -interferer or p75 receptor-interferer of the invention can have the structure:
  • the A ⁇ -interferer or p75 receptor-interferer of the invention can have the structure:
  • R 1 , R 2 , R 3 , Y 1 , Y 2 , and X are as defined above
  • R a and Rt ⁇ are each independently hydrogen, alkyl, aryl, or heterocyclyl, or R a and R ⁇ , taken together with the nitrogen atom to which they are attached, form a cyclic moiety having from 3 to 8 atoms in the ring, and n is an integer from 0 to 6.
  • R a and Rt ⁇ are each hydrogen.
  • a compound of the invention comprises an ⁇ -amino acid (or -amino acid ester), more preferably a L- ⁇ - amino acid or ester.
  • the Z, R 1 , R 2 , R 3 , Y 1 , Y 2 and X groups are each independently selected such that the biodistribution of the A ⁇ -interferer or p75 receptor-interferer for an intended target site is not prevented while maintaining activity of the A ⁇ -interferer or p75 receptor-interferer.
  • the number of anionic groups (and the overall charge on the therapeutic compound) should not be so great as to prevent traversal of an anatomical barrier, such as a cell membrane, or entry across a physiological barrier, such as the blood-brain barrier, in situations where such properties are desired.
  • esters of phosphonoformate have biodistribution properties different from, and in some cases superior to, the biodistribution properties of phosphonoformate (see, e.g., U.S. Patent Nos. 4,386,081 and 4,591583 to Helgstrand et al., and U.S. Patent Nos. 5,194,654 and 5,463,092 to Hostetler et al.).
  • at least one of R 1 and R 2 is an aliphatic group (more preferably an alkyl group), in which the aliphatic group has between 10 and 24 carbons atoms in the straight or branched chain.
  • the number, length, and degree of branching of the aliphatic chains can be selected to provide a desired characteristic, e.g., lipophilicity.
  • at least one of R 1 and R 2 is an aliphatic group (more preferably an alkyl group), in which the aliphatic group has between 1 and 10 carbons atoms in the straight or branched chain.
  • the number, length, and degree of branching of the aliphatic chains can be selected to provide a desired characteristic, e.g., lipophilicity or ease of ester cleavage by enzymes.
  • a preferred aliphatic group is an ethyl group.
  • the A ⁇ -interferer or p75 receptor-interferer of the invention can have the structure:
  • G represents hydrogen or one or more substituents on the aryl ring (e.g., alkyl, aryl, halogen, amino, and the like) and L is a substituted alkyl group (in certain embodiments, preferably a lower alkyl), more preferably a hydroxy-substituted alkyl or an alkyl substituted with a nucleoside base.
  • G is hydrogen or an electron-donating group.
  • G is preferably an electron withdrawing group at the meta position.
  • electron- withdrawing group is known in the art, and, as used herein, refers to a group which has a greater electron- withdrawing than hydrogen.
  • electron- withdrawing groups include halogens (e.g., fluoro, chloro, bromo, and iodo groups), nitro, cyano, and the like.
  • halogens e.g., fluoro, chloro, bromo, and iodo groups
  • nitro, cyano and the like.
  • electron-donating group refers to a group which is less electron- withdrawing than hydrogen. In embodiments in which G is an electron donating group, G can be in the ortho, meta or para position.
  • L is a moiety selected from the group consisting of :
  • Table 1 lists data pertinent to the characterization of these compounds using art- recognized techniques.
  • the compounds IVa-IVg in Table 1 are corresponding to the following structure, in which L is a group selected from the above-listed (Groups IVa- IVg) with the same number.
  • An anionic group (i.e., a phosphonate or carboxylate group) of an A ⁇ -interferer or a p75 receptor-interferer of the invention is a negatively charged moiety that, in certain preferred embodiments, can modulate interaction between an A ⁇ -peptide and a component of a basement membrane, e.g., GAG or the p75 receptor, to, for example, modulate the formation of A ⁇ -fibrils or cell death.
  • the structure of some of the A ⁇ -interferers or p75 receptor- interferers of this invention includes asymmetric carbon atoms. It is to be understood accordingly that the isomers (e.g., enantiomers and diastereomers) arising from such asymmetry are included within the scope of this invention. Such isomers can be obtained in substantially pure form by classical separation techniques and by sterically controlled synthesis. For the purposes of this application, unless expressly noted to the contrary, an A ⁇ -interferer or a p75 receptor-interferer shall be construed to include both the R or S stereoisomers at each chiral center.
  • an A ⁇ -interferer or a p75 receptor-interferer of the invention comprises a cation (i.e., in certain embodiments, at least one of R 1 , R 2 or R 3 is a cation).
  • the cationic group is hydrogen, H +
  • the A ⁇ -interferer or p75 receptor- interferer is considered an acid, e.g., phosphonoformic acid.
  • the A ⁇ -interferer or p75 receptor-interferer is a salt of the acid.
  • Pharmaceutically acceptable salts of the A ⁇ -interferer or p75 receptor-interferer are within the scope of the invention.
  • R 1 , R 2 or R 3 can be a pharmaceutically acceptable alkali metal (e.g., Li, Na, or K), ammonium cation, alkaline earth cation (e.g., Ca + , Ba 2+ , Mg + ), higher valency cation, or polycationic counter ion (e.g., a polyammonium cation).
  • alkali metal e.g., Li, Na, or K
  • ammonium cation e.g., alkaline earth cation (e.g., Ca + , Ba 2+ , Mg + ), higher valency cation, or polycationic counter ion (e.g., a polyammonium cation).
  • alkaline earth cation e.g., Ca + , Ba 2+ , Mg +
  • polycationic counter ion e.g., a polyammonium cation
  • an anionic compound to a salt-forming counterion (if any) will vary depending on the charge of the anionic portion of the compound (if any) and the charge of the counterion.
  • Preferred pharmaceutically acceptable salts include a sodium, potassium or calcium salt, but other salts are also contemplated within their pharmaceutically acceptable range.
  • pharmaceutically acceptable esters refers to the relatively non-toxic, esterified products of the A ⁇ -interferers or p75 receptor- interferers of the present invention.
  • esters can be prepared in situ during the final isolation and purification of the A ⁇ -interferers or p75 receptor-interferers or by separately reacting the purified A ⁇ -interferer or p75 receptor-interferer in its free acid form or hydroxyl with a suitable esterifying agent; either of which are methods known to those skilled in the art.
  • Carboxylic acids and phosphonic acids can be converted into esters according to methods well known to one of ordinary skill in the art, e.g., via treatment with an alcohol in the presence of a catalyst.
  • a preferred ester group (e.g., when R 3 is lower alkyl) is an ethyl ester group.
  • alkyl refers to the saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
  • a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chain, C3-C30 for branched chain), and more preferably 20 or fewer.
  • preferred cycloalkyls have from 4-10 carbon atoms in their ring structure, and more preferably have 4-7 carbon atoms in the ring structure.
  • lower alkyl refers to alkyl groups having from 1 to 6 carbons in the chain, and to cycloalkyls having from 3 to 6 carbons in the ring structure.
  • alkyl (including “lower alkyl) as used throughout the specification and claims is intended to include both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoro
  • alkoxy refers to a moiety having the structure -O- alkyl, in which the alkyl moiety is described above.
  • aryl as used herein includes 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, unsubstituted or substituted benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
  • Aryl groups also include polycyclic fused aromatic groups such as naphthyl, quinolyl, indolyl, and the like. The aromatic ring can be substituted at one or more ring positions with such substituents, e.g., as described above for alkyl groups.
  • Preferred aryl groups include unsubstituted and substituted phenyl groups.
  • aryloxy refers to a group having the structure -O-aryl, in which the aryl moiety is as defined above.
  • amino refers to an unsubstituted or substituted moiety of the formula -NR a R, in which R a and Rt ⁇ are each independently hydrogen, alkyl, aryl, or heterocyclyl, or R a and Rt ⁇ , taken together with the nitrogen atom to which they are attached, form a cyclic moiety having from 3 to 8 atoms in the ring.
  • amino is intended to include cyclic amino moieties such as piperidinyl or pyrrolidinyl groups, unless otherwise stated.
  • amino-substituted amino group refers to an amino group in which at least one of R a and Rt ⁇ , is further substituted with an amino group.
  • R 1 or R 2 can be (for at least one occurrence) a long- chain aliphatic moiety.
  • long-chain aliphatic moiety refers to a moiety having a straight or branched chain aliphatic moiety (e.g., an alkyl or alkenyl moiety) having from 10 to 24 carbons in the aliphatic chain, e.g., the long-chain aliphatic moiety is an aliphatic chain of a fatty acid (preferably a naturally-occurring fatty acid).
  • Representative long-chain aliphatic moieties include the aliphatic chains of stearic acid, oleic acid, linolenic acid, and the like.
  • the A ⁇ -interferer or p75 receptor-interferer of the invention can have the structure:
  • R 1 and R 2 are each independently hydrogen, an aliphatic group (preferably a branched or straight-chain aliphatic moiety having from 1 to 24 carbon atoms, more preferably 10-24 carbon atoms, in the chain; or an unsubstituted or substituted cyclic aliphatic moiety having from 4 to 7 carbon atoms in the aliphatic ring), an aryl group, a heterocyclic group, or a salt-forming cation;
  • R 3 is hydrogen, lower alkyl, aryl, or a salt- forming cation;
  • Y 1 and Y 2 are each independently hydrogen, halogen (e.g., F, Cl, Br, or I), lower alkyl, hydroxy, alkoxy, or aryloxy; and n is an integer from 0 to 12; such that amyloid deposition is modulated.
  • a ⁇ -interferers or p75 receptor-interferers of the invention prevent or inhibit amyloid deposition in a subject to which the A ⁇ -interferer or p75 receptor-interferer is administered.
  • Preferred A ⁇ - interferers or p75 receptor-interferers for use in the invention include compounds in which both R 1 and R 2 are pharmaceutically acceptable salt-forming cations.
  • R 1 , R 2 and R 3 are each independently a sodium, potassium or calcium cation, and n is 0.
  • Y 1 and Y 2 are each hydrogen.
  • Particularly preferred A ⁇ - interferers or p75 receptor-interferers are salts of phosphonoformate.
  • Trisodium phosphonoformate (foscarnet sodium or Foscavir®) is commercially available (e.g., from Astra), and its clinical pharmacology has been investigated (see, e.g., "Physician's Desk Reference", 51st Ed., pp. 541-545 (1997)).
  • the A ⁇ -interferer or p75 receptor-interferer used in the invention can be an aminophosphonate, a bisphosphonate, a phosphonocarboxylate derivative, a phosphonate derivative, or a phosphono carbohydrate.
  • the A ⁇ -interferer or p75 receptor-interferer can be one of the compounds described in Appendix A submitted herewith.
  • the A ⁇ -interferer or p75 receptor-interferer can be administered in a pharmaceutically acceptable formulation.
  • the present invention pertains to any pharmaceutically acceptable formulations, such as synthetic or natural polymers in the form of macromolecular complexes, nanocapsules, microspheres, or beads, and lipid-based formulations including oil-in-water emulsions, micelles, mixed micelles, synthetic membrane vesicles, and resealed erythrocytes.
  • the pharmaceutically acceptable formulations comprise a polymeric matrix.
  • polymer or “polymeric” are art-recognized and include a structural framework comprised of repeating monomer units which is capable of delivering an A ⁇ - interferer or a p75 receptor-interferer, such that treatment of a targeted condition, e.g., a CNS injury, occurs.
  • the terms also include co-polymers and homopolymers e.g., synthetic or naturally occurring. Linear polymers, branched polymers, and cross-linked polymers are also meant to be included.
  • polymeric materials suitable for forming the pharmaceutically acceptable formulation employed in the present invention include naturally derived polymers such as albumin, alginate, cellulose derivatives, collagen, fibrin, gelatin, and polysaccharides, as well as synthetic polymers such as polyesters (PLA, PLGA), polyethylene glycol, poloxomers, polyanhydrides, and pluronics.
  • Naturally derived polymers such as albumin, alginate, cellulose derivatives, collagen, fibrin, gelatin, and polysaccharides
  • synthetic polymers such as polyesters (PLA, PLGA), polyethylene glycol, poloxomers, polyanhydrides, and pluronics.
  • These polymers are biocompatible with the nervous system, including the central nervous system, they are biodegradable within the central nervous system without producing any toxic byproducts of degradation, and they possess the ability to modify the manner and duration of A ⁇ - interferer or p75 receptor-interferer release by manipulating the polymer's kinetic characteristics.
  • biodegradable means that the polymer will degrade over time by the action of enzymes, by hydro lytic action and/or by other similar mechanisms in the body of the subject.
  • biocompatible means that the polymer is compatible with a living tissue or a living organism by not being toxic or injurious and by not causing an immunological rejection.
  • Polymers can be prepared using methods known in the art (Sandier, S. R.; Karo, W. Polymer Syntheses; Harcourt Brace: Boston, 1994; Shalaby, W.; Ikada, Y.; Langer, R.; Williams, J. Polymers of Biological and Biomedical Significance (ACS Symposium Series 540; American Chemical Society: Washington, DC, 1994). Polymers can be designed to be flexible; the distance between the bioactive side-chains and the length of a linker between the polymer backbone and the group can be controlled. Other suitable polymers and methods for their preparation are described in U.S. Patent Nos. 5,455,044 and 5,576,018, the contents of which are inco ⁇ orated herein by reference.
  • the polymeric formulations are preferably formed by dispersion of the A ⁇ - interferer or p75 receptor-interferer within liquefied polymer, as described in U.S. Pat. No. 4,883,666, the teachings of which are incorporated herein by reference, or by such methods as bulk polymerization, interfacial polymerization, solution polymerization and ring polymerization as described in Odian G., Principles of Polymerization and ring opening polymerization, 2nd ed., John Wiley & Sons, New York, 1981, the contents of which are incorporated herein by reference.
  • the properties and characteristics of the formulations are controlled by varying such parameters as the reaction temperature, concentrations of polymer and A ⁇ -interferer or p75 receptor-interferer, types of solvent used, and reaction times.
  • the pharmaceutically acceptable formulation used in the method of the invention can comprise additional pharmaceutically acceptable carriers and/or excipients.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and anti fungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • the carrier can be suitable for injection into the cerebrospinal fluid.
  • Excipients include pharmaceutically acceptable stabilizers and disintegrants.
  • the A ⁇ -interferer or p75 receptor-interferer can be encapsulated in one or more pharmaceutically acceptable polymers, to form a microcapsule, microsphere, or microparticle, terms used herein interchangeably.
  • Microcapsules, microspheres, and microparticles are conventionally free-flowing powders consisting of spherical particles of 2 millimeters or less in diameter, usually 500 microns or less in diameter. Particles less than 1 micron are conventionally referred to as nanocapsules, nanoparticles or nanospheres.
  • the difference between a microcapsule and a nanocapsule, a microsphere and a nanosphere, or microparticle and nanoparticle is size; generally there is little, if any, difference between the internal structure of the two.
  • the mean average diameter is less than about 45 ⁇ m, preferably less than 20 ⁇ m, and more preferably between about 0.1 and 10 ⁇ m.
  • the pharmaceutically acceptable formulations comprise lipid-based formulations. Any of the known lipid-based drug delivery systems can be used in the practice of the invention.
  • multivesicular liposomes can all be used so long as a sustained release rate of the encapsulated A ⁇ - interferer or p75 receptor-interferer can be established.
  • the lipid- based formulation can be a multivesicular liposome system.
  • composition of the synthetic membrane vesicle is usually a combination of phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used.
  • lipids useful in synthetic membrane vesicle production include phosphatidylglycerols, phosphatidylcholines, phosphatidylserines, phosphatidylethanolamines, sphingolipids, cerebrosides, and gangliosides.
  • phospholipids including egg phosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, and dioleoylphosphatidylglycerol are used.
  • the A ⁇ -interferer or p75 receptor-interferer is administered by introduction into the central nervous system of the subject, e.g., into the cerebrospinal fluid of the subject.
  • the A ⁇ -interferer or p75 receptor-interferer is introduced intrathecally, e.g., into a cerebral ventricle, the lumbar area, or the cisterna magna.
  • the pharmaceutically acceptable formulations can easily be suspended in aqueous vehicles and introduced through conventional hypodermic needles or using infusion pumps. Prior to introduction, the formulations can be sterilized with, preferably, gamma radiation or electron beam sterilization, described in US patent no. 436,742 the contents of which are incorporated herein by reference.
  • the A ⁇ -interferer or p75 receptor- interferer formulation is administered into a subject intrathecally.
  • the term "intrathecal administration" is intended to include delivering an A ⁇ -interferer or p75 receptor-interferer formulation directly into the cerebrospinal fluid of a subject, by techniques including lateral cerebroventricular injection through a burrhole or cisternal or lumbar puncture or the like (described in Lazorthes et al. Advances in Drug Delivery Systems and Applications in Neurosurgery, 143-192 and Omaya et al., Cancer Drug Delivery, 1: 169-179, the contents of which are inco ⁇ orated herein by reference).
  • lumbar region is intended to include the area between the third and fourth lumbar (lower back) vertebrae.
  • ceisterna magna is intended to include the area where the skull ends and the spinal cord begins at the back of the head.
  • cervical ventricle is intended to include the cavities in the brain that are continuous with the central canal of the spinal cord.
  • Administration of an A ⁇ -interferer or p75 receptor- interferer to any of the above mentioned sites can be achieved by direct injection of the A ⁇ -interferer or p75 receptor-interferer formulation or by the use of infusion pumps.
  • the A ⁇ -interferer or p75 receptor-interferer formulation of the invention can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution.
  • the A ⁇ -interferer or p75 receptor-interferer formulation may be formulated in solid form and re-dissolved or suspended immediately prior to use. Lyophihzed forms are also included.
  • the injection can be, for example, in the form of a bolus injection or continuous infusion (e.g., using infusion pumps) of the A ⁇ -interferer or p75 receptor-interferer formulation.
  • the pharmaceutically acceptable formulation provides sustained delivery, e.g., "slow release" of the A ⁇ - interferer or p75 receptor-interferer to a subject for at least one, two, three, or four weeks after the pharmaceutically acceptable formulation is administered to the subject.
  • sustained delivery is intended to include continual delivery of an A ⁇ -interferer or p75 receptor-interferer in vivo over a period of time following administration, preferably at least several days, a week or several weeks.
  • Sustained delivery of the A ⁇ -interferer or p75 receptor-interferer can be demonstrated by, for example, the continued therapeutic effect of the A ⁇ -interferer or p75 receptor- interferer over time (e.g., sustained delivery of the A ⁇ -interferer or p75 receptor- interferer can be demonstrated by continued inhibition of neuronal cell death over time).
  • sustained delivery of the A ⁇ -interferer or p75 receptor-interferer may be demonstrated by detecting the presence of the A ⁇ -interferer or p75 receptor-interferer in vivo over time.
  • the pharmaceutically acceptable formulation provides sustained delivery of the A ⁇ -interferer or p75 receptor-interferer to a subject for less than 30 days after the A ⁇ -interferer or p75 receptor-interferer is administered to the subject.
  • the pharmaceutically acceptable formulation e.g., "slow release" formulation, can provide sustained delivery of the A ⁇ -interferer or p75 receptor- interferer to a subject for one, two, three or four weeks after the A ⁇ -interferer or p75 receptor-interferer is administered to the subject.
  • the pharmaceutically acceptable formulation may provide sustained delivery of the A ⁇ -interferer or p75 receptor-interferer to a subject for more than 30 days after the A ⁇ -interferer or p75 receptor-interferer is administered to the subject.
  • the pharmaceutical formulation, used in the method of the invention contains a therapeutically effective amount of the A ⁇ -interferer or p75 receptor-interferer.
  • a "therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired result.
  • a therapeutically effective amount of the A ⁇ -interferer or p75 receptor-interferer may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the A ⁇ - interferer or p75 receptor-interferer (alone or in combination with one or more other agents) to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the A ⁇ -interferer or p75 receptor- interferer are outweighed by the therapeutically beneficial effects.
  • a non-limiting range for a therapeutically effective concentration of an A ⁇ -interferer or p75 receptor- interferer is 100 ⁇ M to 1 mM.
  • Neurons e.g., CNS neurons, or isolated neuronal cells can further be contacted with a therapeutically effective amount of a A ⁇ -interferer or p75 receptor-interferer, in vitro.
  • neuronal cells can be isolated from a subject and grown in vitro, using techniques well known in the art. Briefly, a neuronal cell culture can be obtained by allowing neuron cells to migrate out of fragments of neuronal tissue adhering to a suitable substrate (e.g., a culture dish) or by disaggregating the tissue, e.g., mechanically or enzymatically, to produce a suspension of neuronal cells.
  • the enzymes trypsin, collagenase, elastase, hyaluronidase, DNase, pronase, dispase, or various combinations thereof can be used. Trypsin and pronase give the most complete disaggregation but may damage the cells. Collagenase and dispase give a less complete dissagregation but are less harmful.
  • Methods for isolating tissue (e.g., neuronal tissue) and the disaggregation of tissue to obtain cells are described in Freshney R. I., Culture of Animal Cells, A Manual of Basic Technique, Third Edition, 1994, the contents of which are inco ⁇ orated herein by reference.
  • Such cells can be subsequently contacted with an A ⁇ -interferer or p75 receptor- interferer at levels and for a duration of time as described above. Once inhibition of neuronal cell death has been achieved, these neuronal cells can be re-administered to the subject, e.g., by implantation.
  • the present invention further pertains to a method of treating a disease state characterized by A ⁇ -induced and/or p75 receptor-mediated neuronal cell death in a subject.
  • the term "state” is art recognized and includes a disorder, disease or condition characterized by A ⁇ -induced and/or p75 receptor-mediated neuronal cell death. Examples of such disorders include Alzheimer's Disease, dementias related to Alzheimer's disease (such as Pick's disease), Parkinson's and other Lewy diffuse body diseases, multiple sclerosis, amyotrophic lateral sclerosis, progressive supranuclear palsy, and spongioform encephalitis.
  • the invention is further illustrated by the following examples, which should not be construed as further limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby inco ⁇ orated by reference.
  • NGF-differentiated PC- 12 cells were treated with fibrillar A ⁇ 0 or fibrillar A ⁇ 2 in the presence or absence of A ⁇ -interferers.
  • the percentage of dead cells were determined by MTT and SRB (rhodamine based dye - protein count) assays (as described in, for example, Rubinstein L.V. et al. (1990) J. Natl. Cancer Inst. 82 (13): 1113-8) after a 24 hour incubation. Cells were incubated with A ⁇ 40 with same weight compounds at 1 :1 or 1:2 - weigh weight ratio.
  • NC- 1563 4-Amino- 1 -butylphosphonic acid, O disodium salt ,P(ONa)2
  • NC-1668 3-Amino-pentylphosphonic acid, .P ⁇ 3Na 2 disodium salt
  • NC-1669 3-Amino-hexylphosphonic acid, disodium salt
  • NC- 1670 3-Amino-heptylphosphonic acid, disodium salt
  • NC-1680 2-(2-Amino-4- phosphonobutoxy)tetrahydropyran
  • NC- 1715 3-Hydroxy-3-(4-pyridyl)propenyl-2- phosphonic acid, disodium salt
  • NC-1722 1.4-Diamino-4-methyl-l-(4- pyridyl)pentyl-2-phosphonic acid, disodium salt
  • NC-1728 3-(2-Amino-4,5,7,8-tetrahydro-6H- thiazolo[4,5- ⁇ i]azepin-6-y ⁇ )propyl- phosphonic acid, disodium salt NC-1769 N-Phosphonomethylglycine o I I
  • NC-1784 3-[6-Methoxy-2-(l,2,3,4-tetrahydro- isoquinolinyl)]propylphosphonic acid, disodium salt
  • NC-1785 3-[8-Methoxy-2-(l,2,3,4-tetrahydro- isoquinolinyl)]propylphosphonic acid, disodium salt
  • NC-1786 3-[2-(3-Methoxycarbonyl-l, 2,3,4- tetrahydroisoquinolinyiyj- propylphosphonic acid disodium salt
  • NC-1702 Pamidronic acid (3-Aminopropyl-l- P0 3 H 2 hydroxypropane- 1 , 1 -bisphosphomc acid) H 2 N P ⁇ 3 H 2
  • NC- 1733 1 -Amino-3-(methylpentylamino)propane- 1,1 -bisphosphonic acid, tetrasodium salt
  • NC-1736 3-Aminopropane- 1,1 -bisphosphonic acid, H,N-, . ⁇ 3 Na 2 tetrasodium salt POjNaz NC-1737 ( ⁇ /)-3-Aminobutane-l ,1 -bisphosphonic ,P ⁇ 3 Na 2 acid, tetrasodium salt NH 2 P ⁇ 3Na 2
  • NC-1743 (f)-3-Amino-3-methylbutane-l , 1 - ,P ⁇ 3 a 2 bisphosphonic acid, tetrasodium salt NH 2 P ⁇ 3Na 2
  • NC-1745 ( -3-Arnino-4-phenyibutane-l , 1 - bisphosphonic acid, tetrasodium salt NC- 1746 (dl)-3 - Amino-4-pheny lpentane- 1,1 - bisphosphonic acid, tetrasodium salt
  • NC- 1756 4-Amino- 1 -hydroxybutane-1 ,1 - OH
  • NC- 1758 5- Amino- 1 -hydroxypentane- 1,1- OH bisphosphonic acid, tetrasodium salt NH 2 CH 2 CH2CH 2 CH2Cff0 3 Na 2 )2
  • NC-1766 ( /)-3-Amino-l-hydroxy-3- phenylpropane- 1 , 1 -bisphosphonic acid, tetrasodium salt
  • NC-837 Phosphonoacetic acid (See NC-769) HO 2 CCH 2 PO 3 H 2
  • NC-852 D-(-)-2-Amino-7-phosphonoheptanoic CQ > H acid HH.-.. ⁇ ' _ _ P0(0H) 2 H 2 N
  • NC-890 (£,E)-4-(3-Phos ⁇ honoprop-2- enyl)pi ⁇ erazine-2-carboxylic acid
  • NC- 1786 3-[2-(3-Methoxycarbonyl- 1 ,2,3,4- tetrahydroisoquinolinyl)]- propylphosphonic acid disodium salt Ph pnonate derivative
  • NC-831 3-Aminopropylphosphonic acid NH 2 CH 2 CH 2 CH 2 P0 3 H 2
  • NC-833 (1 -Aminopropy l)phosphonic acid
  • NC-860 3- Aminopropy l(methyl)phosphinic acid, 0 hydrochloride HaN ⁇ P-OH • HCI Me
  • NC-1563 4-Amino-l-butylphosphonic acid, o disodium salt .PCONa ⁇
  • NC-1668 3-Amino-pentylphosphonic acid, .P0 3 Na 2 disodium salt
  • NC-1672 3-Amino-4-methyl-pentylphosphonic acid, disodium salt
  • NC-1673 3-Amino-3-methyl-butylphosphonic acid, P ⁇ 3 Na 2 disodium salt
  • NC-1680 2-(2-Amino-4- phosphonobutoxy)tetrahydropyran NC- 1681 3 -Amino-4-hydroxy-butylphosphonic .PO,Na, acid, HO' disodium salt NH,
  • NC-1728 3-(2-Amino-4,5,7,8-tetrahydro-6H- thiazolo[4,5-cf
  • NC-1784 3-[6-Methoxy-2-(l,2,3,4-tetrahydro- isoquinolinyl)]propylphosphonic acid, disodium salt
  • NC-1785 3-[8-Methoxy-2-(l,2,3,4-tetrahydro- isoquinolinyl)]propylphosphonic acid, disodium salt
  • NC-1801 (l,5-Dideoxy-l,5-imino- ⁇ -D- glucopyranosyl)methylphosphonic acid, disodium salt
  • NC-1538 (d/)-2-Amino-3-thiophosphonopropionic NH S acid H ⁇ 2CCHCH 2 P(OH)2
  • NC- 1539 (1 -Aminopropy l)thiophosphonic acid NH 2 S CH j CHzCH-P ⁇ OH ⁇
  • NC-1553 ( ?)-3-(2-Carboxypiperazin-4-yl)-propyl- 1 -thiophosphonic acid
  • NC-1729 3-(2-Amino-4,5,7,8-tetrahydro-6H- S thiazolo[4,5-ci]azepin-6-yl)propyl- ⁇ 2 N- j N- ,P(CfNa)2 thiophosphonic acid, disodium salt

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des méthodes d'inhibition de mort de cellules neuronales induite par Aβ. L'invention concerne en outre des méthodes permettant de fournir une neuroprotection à un sujet et des méthodes de traitement d'un état de maladie caractérisé par une mort de cellule neuronale induite par Aβ chez un sujet. L'invention concerne aussi des méthodes d'inhibition d'une mort de cellule neuronale induite par un récepteur de p75, ainsi que des méthodes de traitement d'un état de maladie chez un sujet se caractérisant par une mort de cellules neuronales induite par un récepteur de p75.
PCT/IB1999/000968 1998-05-15 1999-05-14 Utilisation d'inhibiteurs d'amyloides pour une modulation de mort de cellules neuronales WO1999059571A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002333203A CA2333203A1 (fr) 1998-05-15 1999-05-14 Utilisation d'inhibiteurs d'amyloides pour une modulation de mort de cellules neuronales
EP99919499A EP1077690A1 (fr) 1998-05-15 1999-05-14 Utilisation d'inhibiteurs d'amyloides pour une modulation de mort de cellules neuronales
AU37262/99A AU3726299A (en) 1998-05-15 1999-05-14 Use of amyloid inhibitors for modulating neuronal cell death
IL13968899A IL139688A0 (en) 1998-05-15 1999-05-14 Use of amyloid inhibitors for modulating neuronal cell death
JP2000549236A JP2002515429A (ja) 1998-05-15 1999-05-14 ニューロン細胞死を調節する方法
MXPA00011213A MXPA00011213A (es) 1998-05-15 1999-05-14 Uso de inhibidores de amiloides para la modulacion de la muerte de las celulas neuronales.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8557198P 1998-05-15 1998-05-15
US60/085,571 1998-05-15

Publications (1)

Publication Number Publication Date
WO1999059571A1 true WO1999059571A1 (fr) 1999-11-25

Family

ID=22192515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/000968 WO1999059571A1 (fr) 1998-05-15 1999-05-14 Utilisation d'inhibiteurs d'amyloides pour une modulation de mort de cellules neuronales

Country Status (7)

Country Link
EP (1) EP1077690A1 (fr)
JP (1) JP2002515429A (fr)
AU (1) AU3726299A (fr)
CA (1) CA2333203A1 (fr)
IL (1) IL139688A0 (fr)
MX (1) MXPA00011213A (fr)
WO (1) WO1999059571A1 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085093A2 (fr) * 1999-12-23 2001-11-15 Neurochem, Inc. Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide
WO2004058258A1 (fr) * 2002-12-24 2004-07-15 Neurochem (International) Limited Formulations therapeutiques pour le traitement de maladies liees a la beta-amyl0ide
WO2004112762A2 (fr) * 2003-06-23 2004-12-29 Neurochem (International) Limited Formulations pharmaceutiques de composes inhibiteurs de substances amyloides
WO2005000406A2 (fr) * 2003-06-23 2005-01-06 Neurochem (International) Limited Procedes et compositions pour le traitement de maladies associees au peptide amyloide et a l'epileptogenese
EP1609467A1 (fr) * 1998-07-28 2005-12-28 Neurochem (International) Limited Compositions pour le traitement des maladies associées aux interactions moleculaires des glycosaminoglycanes
WO2008099210A2 (fr) 2007-02-12 2008-08-21 Merck & Co., Inc. Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées
US8748656B2 (en) 2006-10-12 2014-06-10 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9175094B2 (en) 2007-06-12 2015-11-03 Ac Immune S.A. Monoclonal antibody
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
CN105637093A (zh) * 2013-08-28 2016-06-01 荷兰皇家科学院 转导缓冲液
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
WO2023212289A1 (fr) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate pour le traitement de maladies liées à apoe4
WO2024119183A1 (fr) 2022-12-02 2024-06-06 Alzheon, Inc. Méthodes de traitement de troubles neurodégénératifs avec du tramiprosate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022437A2 (fr) * 1993-03-29 1994-10-13 Queen's University At Kingston Procede de traitement de l'amyloïdose
WO1996028187A1 (fr) * 1995-03-15 1996-09-19 Queen's University At Kingston Procedes de traitement de l'amylose
WO1999008685A1 (fr) * 1997-08-18 1999-02-25 Queen's University At Kingston Composes de phosphono-carboxylate conçus pour le traitement de l'amylose
WO1999040909A1 (fr) * 1998-02-11 1999-08-19 Neurochem, Inc. Methode de modulation de l'activation des macrophages

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022437A2 (fr) * 1993-03-29 1994-10-13 Queen's University At Kingston Procede de traitement de l'amyloïdose
WO1996028187A1 (fr) * 1995-03-15 1996-09-19 Queen's University At Kingston Procedes de traitement de l'amylose
WO1999008685A1 (fr) * 1997-08-18 1999-02-25 Queen's University At Kingston Composes de phosphono-carboxylate conçus pour le traitement de l'amylose
WO1999040909A1 (fr) * 1998-02-11 1999-08-19 Neurochem, Inc. Methode de modulation de l'activation des macrophages

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A COPANI ET AL: "ACTIVATION OF METABOTROPIC GLUTAMATE RECEPTORS PROTECTS CULTURED NEURONS AGAINST APOPTOSIS INDUCED BY beta-AMYLOID PEPTIDE", MOLECULAR PHARMACOLOGY, vol. 5, no. 47, 1 January 1995 (1995-01-01), pages 890 897, XP002079923, ISSN: 0026-895X *
KISILEVSKY R ET AL: "ARRESTING AMYLOIDOSIS IN VIVO USING SMALL-MOLECULE ANIONIC SULPHONATES OR SULPHATES: IMPLICATIONS FOR ALZHEIMER'S DISEASE", NATURE MEDICINE, vol. 1, no. 2, 1 February 1995 (1995-02-01), pages 143 - 148, XP000611547, ISSN: 1078-8956 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1609467A1 (fr) * 1998-07-28 2005-12-28 Neurochem (International) Limited Compositions pour le traitement des maladies associées aux interactions moleculaires des glycosaminoglycanes
WO2001085093A3 (fr) * 1999-12-23 2002-08-29 Neurochem Inc Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide
US6670399B2 (en) 1999-12-23 2003-12-30 Neurochem (International) Limited Compounds and methods for modulating cerebral amyloid angiopathy
WO2001085093A2 (fr) * 1999-12-23 2001-11-15 Neurochem, Inc. Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide
EA012325B1 (ru) * 2002-12-24 2009-08-28 Беллус Хелс (Интернэшнл) Лимитед Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
WO2004058258A1 (fr) * 2002-12-24 2004-07-15 Neurochem (International) Limited Formulations therapeutiques pour le traitement de maladies liees a la beta-amyl0ide
WO2004058239A1 (fr) * 2002-12-24 2004-07-15 Neurochem (International) Limited Formulations therapeutiques destinees au traitement de maladies liees au peptide beta-amyloide
AU2003291910B2 (en) * 2002-12-24 2009-10-01 Bellus Health (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US10464976B2 (en) 2003-01-31 2019-11-05 AbbVie Deutschland GmbH & Co. KG Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
WO2004112762A3 (fr) * 2003-06-23 2005-06-02 Neurochem Int Ltd Formulations pharmaceutiques de composes inhibiteurs de substances amyloides
WO2005000406A2 (fr) * 2003-06-23 2005-01-06 Neurochem (International) Limited Procedes et compositions pour le traitement de maladies associees au peptide amyloide et a l'epileptogenese
WO2005000406A3 (fr) * 2003-06-23 2005-06-23 Neurochem Int Ltd Procedes et compositions pour le traitement de maladies associees au peptide amyloide et a l'epileptogenese
EP2127648A1 (fr) * 2003-06-23 2009-12-02 BELLUS Health (International) Limited Formulations pharmaceutiques de composés d'inhibition amyloïde
WO2004112762A2 (fr) * 2003-06-23 2004-12-29 Neurochem (International) Limited Formulations pharmaceutiques de composes inhibiteurs de substances amyloides
US8835500B2 (en) 2003-06-23 2014-09-16 BHI Limited Partership Pharmaceutical formulations of amyloid inhibiting compounds
US10323084B2 (en) 2005-11-30 2019-06-18 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US11020360B2 (en) 2006-10-12 2021-06-01 Bellus Health Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US10857109B2 (en) 2006-10-12 2020-12-08 Bellus Health, Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8748656B2 (en) 2006-10-12 2014-06-10 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US10238611B2 (en) 2006-10-12 2019-03-26 Bellus Health Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US9951125B2 (en) 2006-11-30 2018-04-24 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
WO2008099210A2 (fr) 2007-02-12 2008-08-21 Merck & Co., Inc. Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9585956B2 (en) 2007-06-12 2017-03-07 Ac Immune S.A. Polynucleotides encoding anti-amyloid beta monoclonal antibodies
US9175094B2 (en) 2007-06-12 2015-11-03 Ac Immune S.A. Monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9822171B2 (en) 2010-04-15 2017-11-21 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US10047121B2 (en) 2010-08-14 2018-08-14 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CN105637093A (zh) * 2013-08-28 2016-06-01 荷兰皇家科学院 转导缓冲液
CN105637093B (zh) * 2013-08-28 2021-04-06 荷兰皇家科学院 转导缓冲液
WO2023212289A1 (fr) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate pour le traitement de maladies liées à apoe4
WO2024119183A1 (fr) 2022-12-02 2024-06-06 Alzheon, Inc. Méthodes de traitement de troubles neurodégénératifs avec du tramiprosate

Also Published As

Publication number Publication date
MXPA00011213A (es) 2003-04-22
AU3726299A (en) 1999-12-06
CA2333203A1 (fr) 1999-11-25
JP2002515429A (ja) 2002-05-28
EP1077690A1 (fr) 2001-02-28
IL139688A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
US6670399B2 (en) Compounds and methods for modulating cerebral amyloid angiopathy
WO1999059571A1 (fr) Utilisation d'inhibiteurs d'amyloides pour une modulation de mort de cellules neuronales
US20080249184A1 (en) Methods for modulating neuronal cell death
CA2320224C (fr) Methode de modulation de l'activation des macrophages
US20040096453A1 (en) Methods and compositions to treat glycosaminoglycan-associated molecular interactions
AU2243199A (en) Phosphono-carboxylate compounds for treating amyloidosis
CA2300910C (fr) Composes de phosphono-carboxylate concus pour le traitement de l'amylose
AU2006203051B2 (en) Use of amyloid inhibitors for modulating neuronal cell death
AU2008207470A1 (en) Use of amyloid inhibitors for modulating neuronal cell death
AU2006201445A1 (en) Compounds and methods for modulating cerebral amyloid angiopathy
AU2006228064B2 (en) Method for modulating macrophage activation
AU2004202703A1 (en) Methods and compositions to treat glycosaminoglycan-associated molecular interactions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2333203

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 139688

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/011213

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 37262/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999919499

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999919499

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642